Evidence map›Paper›PMID 26150775›Full record

ArticleFrontiers in behavioral neuroscience2015

AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role.

Kuang-Ti Chen, Mang-Hung Tsai, Ching-Hsiang Wu, Ming-Jia Jou, I-Hua Wei, Chih-Chia Huang

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04975100 (Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04975100 phase4completednot on this mapstarted 2021, after this paper: background citation

Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2021 to 2023Enrolled60ConditionsMajor Depressive DisorderArmsSarcosine and SSRI, Placebo and SSRI
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Modulation of the activity ofNeuropsychiatric disease and treatment · 2017
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Kuang-Ti ChenInstitute of Basic Medical Science, China Medical University , Taichung , Taiwan.
Mang-Hung TsaiDepartment of Anatomy, China Medical University , Taichung , Taiwan.
Ching-Hsiang WuDepartment of Anatomy, College of Medicine, Taipei Medical University , Taipei , Taiwan.
Ming-Jia JouSchool of Chinese Medicine for Post Baccalaureate, I-Shou University , Kaohsiung , Taiwan.
I-Hua WeiDepartment of Anatomy, China Medical University , Taichung , Taiwan.
Chih-Chia HuangDepartment of Psychiatry, China Medical University Hospital , Taichung , Taiwan ; Institute of Clinical Medical Science, China Medical University , Taichung , Taiwan ; Department of Psychiatry, China Medical University , Taichung , Taiwan.
China Medical University · TWChina Medical University Hospital · TWI-Shou University · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcosine, an endogenous amino acid, is a competitive inhibitor of the type I glycine transporter and an N-methyl-d-aspartate receptor (NMDAR) coagonist. Recently, we found that sarcosine, an NMDAR enhancer, can improve depression-related behaviors in rodents and humans. This result differs from previous studies, which have reported antidepressant effects of NMDAR antagonists. The mechanisms underlying the therapeutic response of sarcosine remain unknown. This study examines the role of mammalian target of rapamycin (mTOR) signaling and α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor (AMPAR) activation, which are involved in the antidepressant-like effects of several glutamatergic system modulators. The effects of sarcosine in a forced swim test (FST) and the expression levels of phosphorylated mTOR signaling proteins were examined in the absence or presence of mTOR and AMPAR inhibitors. In addition, the influence of sarcosine on AMPAR trafficking was determined by analyzing the phosphorylation of AMPAR subunit GluR1 at the PKA site (often considered an indicator for GluR1 membrane insertion in neurons). A single injection of sarcosine exhibited antidepressant-like effects in rats in the FST and rapidly activated the mTOR signaling pathway, which were significantly blocked by mTOR inhibitor rapamycin or the AMPAR inhibitor 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) pretreatment. Moreover, NBQX pretreatment eliminated the ability of sarcosine to stimulate the phosphorylated mTOR signaling proteins. Furthermore, GluR1 phosphorylation at its PKA site was significantly increased after an acute in vivo sarcosine treatment. The results demonstrated that sarcosine exerts antidepressant-like effects by enhancing AMPAR-mTOR signaling pathway activity and facilitating AMPAR membrane insertion. Highlights-A single injection of sarcosine rapidly exerted antidepressant-like effects with a concomitant increase in the activation of the mammalian target of rapamycin mTOR signaling pathway.-The antidepressant-like effects of sarcosine occur through the activated AMPAR-mTOR signaling pathway.-Sarcosine could enhance AMPAR membrane insertion via an AMPAR throughput.

Indexed as

AMPAdepressionmTORNMDAsarcosine

Identifiers

PMID26150775
PMCPMC4471371
OpenAlexW1589051410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.